Leveraging Next-Gen Sequencing, Bioinformatics & -Omics Technologies to Identify & Validate Novel Targets & Regulatory Elements in the Dark Genome
The Inaugural Dark Genome Target Discovery & Development Summit
The Dawn of the Dark Genome Has Arrived...
With HAYA Therapeutics closing $65M series A financing to continue pioneering LncRNA targeted therapeutics across multiple disease areas, and UbiVac releasing promising clinical data from their vaccine-induced TCR against a dark genome-derived antigen, it is evident the dark genome’s long-hidden potential is finally coming to light.
Crafted to unite the fast-growing community of pioneers, the inaugural Dark Genome Target Discovery & Development Summit is the first industry-focused forum dedicated to deciphering the mysteries of non-coding DNA and RNA to harness its potential across oncology, neuroscience, aging, heart disease and beyond!
In three weeks' time, join world-class experts at ROME Therapeutics, HAYA Therapeutics, Mnemo Therapeutics, HERVolution, CAMP4 Therapeutics, Enara Bio, Immatics and more, to gain the tangible insights and strategies across discovery, genomics, proteomics, data science, AI, bioinformatics and computational biology to enlighten a new paradigm for drug discovery.
Our World-Class Speaker Faculty Features
Is This Meeting the Right Fit for You?
Seeking an industry-focused learning opportunity to advance your understanding?
Looking to scout out potential partnership opportunities with senior industry leaders?
Brand-new to the space and simply want to know what all the hype is about?
Then you have come to the right place. At the Dark Genome Target Discovery & Development Summit, gain a comprehensive overview of the key learnings, technical challenges, and priorities for drug discovery and development in the dark genome, so you can take actionable insights back to your team.
Don't miss your opportunity to connect with key opinion leaders from C-suite to scientist levels working across discovery, bioinformatics, computational biology, AI, data science and -omics, in a collaborative effort to uncover the dark genome’s mysteries, advance technology platforms and propel target discovery.
Proud to Partner With
Network With 50+ Industry Leading Companies Including
